.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
Fuji
Express Scripts
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Farmers Insurance
Dow

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,112,592

« Back to Dashboard

Which drugs does patent 7,112,592 protect, and when does it expire?


Patent 7,112,592 protects AVYCAZ and is included in one NDA.

This patent has fifty-three patent family members in forty-two countries.

Summary for Patent: 7,112,592

Title:Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: ##STR00001## The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
Inventor(s): Lampilas; Maxime (Romainville, FR), Aszodi; Jozsef (Tucson, AZ), Rowlands; David Alan (Poissy, FR), Fromentin; Claude (Paris, FR)
Assignee: Aventis Pharma S.A. (FR)
Application Number:10/343,315
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
CerexaAVYCAZavibactam sodium; ceftazidimePOWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING BACTERIAL INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,112,592

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 10121Aug 1, 2000
PCT Information
PCT FiledJuly 24, 2001PCT Application Number:PCT/FR01/02418
PCT Publication Date:February 07, 2002PCT Publication Number: WO02/10172

Non-Orange Book Patents for Patent: 7,112,592

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,638,529Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
8,178,554Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
7,732,610Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,112,592

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)1614► Subscribe
Argentina031716► Subscribe
Eurasian Patent Organization200300211► Subscribe
Eurasian Patent Organization004920► Subscribe
EcuadorSP034460► Subscribe
Estonia200300046► Subscribe
Estonia05183► Subscribe
European Patent Office1307457► Subscribe
Spain2220793► Subscribe
France2812635► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
US Department of Justice
US Army
Teva
Chinese Patent Office
Cerilliant
Dow
Argus Health
Fuji
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot